These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34449067)

  • 1. Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis.
    Truong SL; Chin J; Liew DFL; Zahir SF; Ryan EG; Rubel D; Radford-Smith G; Robinson PC
    Rheumatol Ther; 2021 Dec; 8(4):1603-1616. PubMed ID: 34449067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
    Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
    JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
    Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
    Xie W; Xiao S; Huang H; Zhang Z
    Front Immunol; 2022; 13():847160. PubMed ID: 35300336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies.
    Aureal M; Seauve M; Laplane S; Lega JC; Cabrera N; Coury F
    RMD Open; 2023 Sep; 9(3):. PubMed ID: 37714666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases.
    Elewaut D; Braun J; Anderson JK; Arikan D; Chen S; Hojnik M; De Craemer AS; Curtis JR
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):289-295. PubMed ID: 32100944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
    Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
    RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
    Emond B; Ellis LA; Chakravarty SD; Ladouceur M; Lefebvre P
    Curr Med Res Opin; 2019 Oct; 35(10):1751-1759. PubMed ID: 31106607
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumor necrosis factor treatment in patients with inflammatory bowel disease does not promote psoriasis development: A meta-analysis.
    Jun YK; Park JY; Koh SJ; Park H; Kang HW; Im JP; Kim JS
    Medicine (Baltimore); 2022 Jul; 101(27):e29872. PubMed ID: 35801760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ni R; Zheng J; Varghese J; Kumar B
    Cureus; 2024 May; 16(5):e60980. PubMed ID: 38910708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
    Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
    Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
    Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
    Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic Treatment Strategies in Psoriatic Arthritis.
    Ayan G; Ribeiro A; Macit B; Proft F
    Clin Ther; 2023 Sep; 45(9):826-840. PubMed ID: 37455227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
    Esse S; Mason KJ; Green AC; Warren RB
    JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature.
    Ali AK; Torosian A; Porter C; Bloomfeld RS; Feldman SR
    Dermatol Ther; 2021 Nov; 34(6):e15151. PubMed ID: 34609037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis.
    Miao XP; Ouyang Q; Li HY; Wen ZH; Zhang DK; Cui XY
    Curr Ther Res Clin Exp; 2008 Jun; 69(3):181-91. PubMed ID: 24692797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated With Biologic Agents Determined Using the BSRBR-AS and a MetaAnalysis.
    Macfarlane GJ; Biallas R; Dean LE; Jones GT; Goodson NJ; Rotariu O
    J Rheumatol; 2023 Feb; 50(2):175-184. PubMed ID: 35777821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.